文献速递脑血管病

心房颤动缺血性卒中患者卒中前抗凝治疗分析

Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation.
PubMed 文献 · Ann Neurol · 2020-10-17

该队列研究纳入2014-2019年8179例心房颤动急性缺血性卒中患者,比较卒中前维生素K拮抗剂或直接口服抗凝药治疗与未抗凝者的卒中严重度、静脉溶栓使用及3个月结局。直接口服抗凝药组入院卒中严重度较低,但静脉溶栓率显著降低,3个月功能结局可能更好。

要点

  • 直接口服抗凝药组入院卒中严重度低于维生素K拮抗剂组和对照组。
  • 维生素K拮抗剂和直接口服抗凝药组静脉溶栓率均显著低于对照组。
  • 直接口服抗凝药预处理与3个月良好功能结局相关。

核心结论

  • 心房颤动患者卒中前直接口服抗凝药治疗与入院卒中严重度降低和极低静脉溶栓率相关,且3个月功能结局可能更好。

研究设计与样本

  • 连续患者队列研究(2014-2019年),比较抗凝治疗者与未抗凝对照者,共8179例,平均年龄79.8岁,49%女性。

主要发现

  • 直接口服抗凝药组卒中严重度中位NIHSS为4(四分位距2-11),低于维生素K拮抗剂组的6(2-14)和对照组的7(3-15),p<0.001。
  • 可能符合静脉溶栓条件的患者中,维生素K拮抗剂组溶栓率63%(156/247;aOR 0.67,95%CI 0.50-0.90),直接口服抗凝药组15%(69/464;aOR 0.06,95%CI 0.05-0.08),对照组74%(1544/2504)。
  • 静脉溶栓后症状性颅内出血率:对照组3.6%(2.6-4.7%),维生素K拮抗剂组4.6%(9/195;aOR 0.93,95%CI 0.46-1.90),直接口服抗凝药组3.1%(2/65;aOR 0.56,95%CI 0.28-1.12)。
  • 调整预后混杂因素后,直接口服抗凝药预处理与3个月良好结局相关(aOR 1.24;95%CI 1.01-1.51)。

临床怎么用

  • 对于服用直接口服抗凝药的心房颤动卒中患者,应关注其静脉溶栓率显著较低的现实,并评估功能结局可能较好的趋势。
  • 临床决策静脉溶栓时需权衡服用维生素K拮抗剂或直接口服抗凝药患者的症状性颅内出血风险与溶栓获益。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to evaluate, in patients with atrial fibrillation (AF) and acute ischemic stroke, the association of prior anticoagulation with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) with stroke severity, utilization of intravenous thrombolysis (IVT), safety of IVT, and 3-month outcomes. METHODS: This was a cohort study of consecutive patients (2014-2019) on anticoagulation versus those without (controls) with regard to stroke severity, rates of IVT/mechanical thrombectomy, symptomatic intracranial hemorrhage (sICH), and favorable outcome (modified Rankin Scale score 0-2) at 3 months. RESULTS: Of 8,179 patients (mean [SD] age, 79.8 [9.6] years; 49% women), 1,486 (18%) were on VKA treatment, 1,634 (20%) on DOAC treatment at stroke onset, and 5,059 controls. Stroke severity was lower in patients on DOACs (median National Institutes of Health Stroke Scale 4, [interquartile range 2-11]) compared with VKA (6, [2-14]) and controls (7, [3-15], p < 0.001; quantile regression: β -2.1, 95% confidence interval [CI] -2.6 to -1.7). The IVT rate in potentially eligible patients was significantly lower in patients on VKA (156 of 247 [63%]; adjusted odds ratio [aOR] 0.67; 95% CI 0.50-0.90) and particularly in patients on DOACs (69 of 464 [15%]; aOR 0.06; 95% CI 0.05-0.08) compared with controls (1,544 of 2,504 [74%]). sICH after IVT occurred in 3.6% (2.6-4.7%) of controls, 9 of 195 (4.6%; 1.9-9.2%; aOR 0.93; 95% CI 0.46-1.90) patients on VKA and 2 of 65 (3.1%; 0.4-10.8%, aOR 0.56; 95% CI 0.28-1.12) of those on DOACs. After adjustments for prognostic confounders, DOAC pretreatment was associated with a favorable 3-month outcome (aOR 1.24; 1.01-1.51). INTERPRETATION: Prior DOAC therapy in patients with AF was associated with decreased admission stroke severity at onset and a remarkably low rate of IVT. Overall, patients on DOAC might have better functional outcome at 3 months. Further research is needed to overcome potential restrictions for IVT in patients taking DOACs. ANN NEUROL 2021;89:42-53.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Meinel TR, Branca M, De Marchis GM, et al. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. Ann Neurol. 2020. PMID: 32996627. doi:10.1002/ana.25917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。